FDA 483 - Sun Pharmaceutical Industries Limited - August 12, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Sun Pharmaceutical Industries Limited in Mohali, India, a drug manufacturer, revealed significant deficiencies across multiple areas. The firm failed to thoroughly investigate discrepancies, including allegations of backdating and confirmed cross-contamination, and exhibited widespread non-contemporaneous documentation practices. Additionally, the inspection found inadequate written procedures for process control, laboratory records, and component testing, indicating a systemic lack of robust quality control and data integrity.
ID · 074bde2f-5ad2-42a9-805b-a497f54eaaaa